Biotechnology Companies in the News – September 2011

Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to send their news releases to BioNJ via email.

September 15

Over 1000 Patients Have Benefited from STENTYS Self-Apposing Technology

September 14

Celgene Corporation to Present at Three Upcoming Investor Conferences

Merck to Present at Bank of America Merrill Lynch Global Healthcare Conference

September 13

Merck and BGI Establish Strategic Collaboration focused on Biomarkers and Genomic Technologies

LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects

Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference

September 12

Costs, Mortality Skyrocket Following Infection in Cardiac Device Recipients

Feds Award Elusys $69 Million to Develop Anthrax Drug

Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer

September 8

Unigene to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011

NPS Pharmaceuticals Announces Hypoparathyroidism Data to be Presented at Annual Meeting of American Society for Bone and Mineral Research

Pfizer And Guoyuan Form Joint Venture To Expand Development, Manufacture And Distribution Of Animal Vaccines In China

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 7

Edge Therapeutics Appoints Dr. Sol J. Barer to Board of Directors

CorMedix to Present at the Rodman & Renshaw Annual Global Investment Conference

Unigene Appoints Industry Veteran Theron (Ted) Odlaug as New Independent Director to Board

September 6

CorMedix Announces Amended Agreement for CRMD001 (a proprietary formulation of deferiprone)

Senesco to Present at 13th Annual Rodman & Renshaw Healthcare Conference

NPS Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference

September 1

New Data from Bristol-Myers Squibb on NULOJIX®(belatacept) to be Presented at the 2011 European Society for Organ Transplantation Congress

August 31

Celgene Corporation to Present at Three Upcoming Investor Conferences

Amicus Therapeutics to Present at Stifel Nicolaus Annual Healthcare Conference on Wednesday, September 7, 2011

August 30

Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference

Global Pharma Leader Will Continue to Leverage Cegedim Relationship Management’s Proven, Reliable and Flexible End-User Services

Unigene Successfully Defends Its Robust Intellectual Property Portfolio

Cyclacel Announces Commencement of Investigator-Initiated Phase 2 Trial of Sapacitabine in Patients with CLL or SLL Hematological Malignancies and 11q22-23 Deletion

August 28

ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial

August 25

Columbia Laboratories to Present at Upcoming Equity Conferences in September

SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC

August 24

Immunomedics Announces Fiscal 2011 Results

ZRG Partners Global Life Science Hiring Index jumps 17.6% in the Second Quarter with Research and Development spending on the Rise

Senesco Finalizes Agreement with Mayo Clinic to Study SNS01-T in Multiple Myeloma

PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection

August 23

Bristol-Myers Squibb And Pfizer Announce Data Presentations For Apixaban At European Society of Cardiology Congress 2011

August 22

Catalent Pharma Solutions Reaches Agreement to Acquire Aptuit LLC’s Clinical Trial Supplies Business

NovaDel Signs Exclusive License and Distribution Agreement with Rechon Life Science AB to Manufacture and Commercialize Zolpimist® outside the US and Canada

Celldex Announces In Vivo Efficacy Data for CDX-1135 in Pediatric Kidney Disease Reported at International Complement Meeting

August 18

NPS Pharmaceuticals Submits Chemistry, Manufacturing and Controls (CMC) Section of New Drug Application for GATTEX®

Celgene Announces Additional $2 Billion Share Repurchase Authorization

August 16

Eisai Expands Into Brazil

Derma Sciences Reports Second Quarter Operating Results

August 15

NPS Pharmaceuticals Announces Amended Amgen Agreement and Plan to Retire Sensipar-Backed Series B Notes

Bristol-Myers Squibb Announces the Winners of the 2011 REYATAZ® (atazanavir sulfate) “Fight HIV Your Way” Contest

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESC Highlights

August 12

Soligenix Reports Second Quarter 2011 Financial Results and Reviews Accomplishments

NovaDel Reports Financial Results for Second Quarter 2011

CorMedix Announces Appointment of Steven W. Lefkowitz to Board of Directors

August 11

Genta Incorporated Reports Second Quarter 2011 Financial Results and Recent Corporate Highlights

Advaxis Completes Pre-IND Meeting for ADXS-PSA

Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference

August 10

Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology

Alliance Life Sciences Releases White Paper: “State and Federal ‘Sunshine Acts’ Shift Key Opinion Leader Marketing Tactics”

Derma Sciences to Hold Second Quarter Financial Results Conference Call on August 16

August 9

Immunomedics to Present at Wedbush Securities 2011 Life Sciences Management Access Conference

CorMedix Reports Second Quarter 2011 Results

Phase 2 Trial of Lexicon’s LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome

Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results

Phase 2 Trial of Lexicon’s LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome

Pharmasset Announces Two-for-One Forward Stock Split

August 8

Antares Pharma Reports Second Quarter 2011 Financial and Operating Results

Top-10 Pharmaceutical Company Renews Support Services Contract with Cegedim Relationship Management

Senesco Technologies Selects Criterium to Manage Multiple Myeloma Study

Tobira Therapeutics Announces Key Management Team Additions

Unigene and GSK Enter Development Services and Clinical Supply Agreement in Preparation of Potential Phase 3 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women

Unigene Reports Second Quarter 2011 Financial Results

Amicus Therapeutics Announces Second Quarter 2011 Financial Results and Multiple Upcoming Milestones

August 7

Pharmasset to Present at Canaccord Genuity Growth Conference

August 4

Unigene to Present at the 2011 Canaccord Genuity Growth Conference on August 9, 2011

Celgene Corporation to Present at 2011 Canaccord Genuity Growth Conference

Columbia Laboratories Reports Second Quarter 2011 Financial Results

Aegerion Pharmaceuticals to Present at the 2011 Canaccord Genuity Growth Conference

Amicus Therapeutics to Present at Canaccord Genuity Growth Conference on Wednesday, August 10, 2011

Antares Pharma Announces Positive study Results with VIBEX™ MTX in Rheumatoid Arthritis Patients

Enzon Reports 2nd Quarter 2011 Results

Lux Biosciences Receives Complete Response Letter from FDA for Luveniq™

August 3

Foundation Venture Capital Group Investment Shows Promise in Diagnosis of Alzheimer’s Disease Using a Drop of Blood

Celldex Reports Second Quarter 2011 Financial Results and Announces Finalization of Rindopepimut Pivotal Program Design

NPS Pharmaceuticals to Present at Canaccord Genuity Growth Conference

Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-536 Program

Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV)

August 2

NPS Pharmaceuticals Reports Second Quarter 2011 Financial Results and Continued Progress on Two Product Registration Programs

NPS Pharmaceuticals Announces New Calcilytics Agreement with GSK

Quintiles, Kadrige Open E-Solutions Operation in the US

Derma Sciences Launches Wound Treatment Video Series on eLearning Portal

Unigene to Announce Second Quarter 2011 Financial Results on August 8, 2011

Antares Pharma to Host Second Quarter 2011 Earnings Call

July 29

Merck Announces Second Quarter 2011 Financial Results

U.S. FDA Provides Response to Perampanel New Drug Application

Amicus Therapeutics Announces John F. Crowley to Return as Chairman and Chief Executive Officer

U.S. Food and Drug Administration Approves Subcutaneous Formulation of ORENCIA® (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis

July 28

Roka Bioscience Completes $20 Million Series C Financing

Advaxis Immunotherapies Classified as Non-Pathogenic Materials by the CDC in the U.S. and the ZKBS in Germany

Soligenix Announces Expansion of Partnership with Sigma-Tau Pharmaceuticals for orBec® in Europe

Lexicon’s IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial

Celgene Reports Record Second Quarter 2011 Operating and Financial Results

Bristol-Myers Squibb Delivers Excellent Second Quarter with Global New Product Approvals, Important Clinical Data and Strong Financial Results

The Medicines Company Appoints Glenn P. Sblendorio to Board of Directors

July 27

Columbia Laboratories Licenses STRIANT Canadian Trademark and Marketing Rights to Invaron Pharmaceuticals Inc.

Aegerion Pharmaceuticals Expands Commercial Leadership With Rare Disease Experience

Aegerion Pharmaceuticals Announces Second-Quarter 2011 Financial Results

Lexicon’s IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial

The Medicines Company Reports Second Quarter and First Half 2011 Results

July 26

NPS Pharmaceuticals to Report Second Quarter 2011 Financial Results

TKL Research Continues to Strengthen Corporate Excellence

Merck Announces Fourth Quarter 2011 Dividend

NICE Endorses Bivalirudin for Heart Attack Patients

July 25

MedNest Incorporates and Launches PharmaNest

Decision Resources Group Acquires PharmaStrat

Advaxis Revises Protocol for CIN Study

Celldex Therapeutics to Report Second Quarter 2011 Financial Results and Host Corporate 2011 Objectives Update Call

Tianjin International Joint Academy of Biotechnology and Medicine (TJAB) and Legacy Healthcare Enter into Agreement for the Development of LH Hair & Scalp Portfolio in China

July 22

Aegerion Pharmaceuticals Appoints Dr. Mark Sumeray as Chief Medical Officer

July 21

Merck and Simcere Sign Agreement to Establish Pioneering China Joint Venture

Aegerion Pharmaceuticals Announces Appointment of Paul G. Thomas to Its Board of Directors

Bristol-Myers Squibb to Acquire Amira Pharmaceuticals

July 20

Labor Puts Focus on Manufacturing, Health Care, Others in Building Talent Networks

ViroStatics CEO, Franco Lori, MD, Presents Late Breaker on Novel AV-HALT HIV Therapy at the 2011 International AIDS Society Pathogenesis Conference

Data on Bristol-Myers Squibb’s Investigational Treatment for Alzheimer’s Disease Demonstrate Potential Therapeutic Window at Doses Below 100 mg in Phase II Safety and Tolerability Study

Pharmasset Announces Final SVR Data from PROTON trial with PSI-7977 in Subjects Infected with Hepatitis C Infection Genotype 2 or 3

July 19

Aegerion Pharmaceuticals to Announce Second-Quarter 2011 Financial Results on Wednesday, July 27

FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin

July 18

Rigosertib’s Arresting Story

July 8

Onconova and SymBio Complete Licensing Agreement for Rigosertib, a Phase III Stage Multi-Kinase Inhibitor for Cancer